Tag: Nicox
Nicox: Plan to transfer the listing of shares to Euronext Growth Paris – 01/09/2023 at 07:37
Nicox SA (Euronext Paris: FR0013018124, COX, PEA-PME eligible), an international company specializing in ophthalmology, today announces its intention to transfer the listing of its shares from the regulated market Euronext…
Nicox, largest drop in the SRD at the close of Wednesday, December 21, 2022 – 12/21/2022 at 6:06 p.m.
(AOF) – Nicox (-4.26% to 1.07 euros) The biotech specializing in ophthalmology suffered a fifth session of decline, losing 8.49%: it lost more than 36% of its value in one…
Nicox: Development and partnership plans for NCX 470 in glaucoma – 07/11/2022 at 07:37
Nicox SA, an international company specializing in ophthalmology, today announces development and partnership plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 clinical…
Clinical results not so bad at Nicox
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? Sale ? What course objective? Our experts engage and…
Nicox: positive phase 3 data in glaucoma – 10/31/2022 at 08:18
(CercleFinance.com) – The Nicox ophthalmology laboratory announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required…
Nicox: NCX 470 has achieved the primary objective of the Mont Blanc study (glaucoma) – 31/10/2022 at 10:07
(AOF) – Nicox SA, an international specialty ophthalmology company, today announces that NCX 470 0.1% administered once daily has achieved the primary endpoint of non-inferiority in the reduction of intraocular…
Nicox: positive phase 3 data in glaucoma
(CercleFinance.com) – The ophthalmology laboratory Nicox announces that the first of two phase 3 studies on its NCX 470 in glaucoma, the Mont Blanc study, has reached the efficacy required…
Nicox: last patient visit for the phase III study – 09/19/2022 at 10:53
(CercleFinance.com) – Nicox announced on Monday that it had completed the last patient visit as part of its phase III clinical study devoted to eye drops NCX 470 in the…
Nicox: Last Patient Visit for Phase III Study
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Nicox: Participation in financial and scientific conferences in the third quarter of 2022
Press release Nicox: Participation in financial and scientific conferences in the third quarter of 2022 August 3, 2022 – broadcast at…
Nicox: Participation in financial and scientific conferences in the third quarter of 2022
Press release Nicox: Participation in financial and scientific conferences in the third quarter of 2022 August 3, 2022 – broadcast at…
Nicox: Financial summary and activity update for the second quarter of 2022 – 07/20/2022 at 07:40
Nicox, an international company specializing in ophthalmology, presents a financial summary and the main activities of Nicox SA and its subsidiaries (the “Nicox group”) for the second quarter of 2022…